BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33931261)

  • 1. Different risk factors for three major recurrence patterns of pathological stage II or III gastric cancer patients who completed adjuvant S-1 monotherapy.
    Kano Y; Ohashi M; Muneoka Y; Takahari D; Chin K; Yamaguchi K; Ida S; Kumagai K; Makuuchi R; Sano T; Nunobe S
    Eur J Surg Oncol; 2021 Dec; 47(12):3097-3104. PubMed ID: 33931261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy.
    Takahashi R; Ohashi M; Kano Y; Ida S; Kumagai K; Nunobe S; Chin K; Yamaguchi K; Nagino M; Sano T; Hiki N
    Gastric Cancer; 2019 Nov; 22(6):1256-1262. PubMed ID: 30877407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence patterns after curative gastrectomy for pStage II/III gastric cancer: Exploratory analysis of the randomized controlled JCOG1001 trial.
    Toriumi T; Terashima M; Mizusawa J; Sato Y; Kurokawa Y; Takiguchi S; Doki Y; Shinohara H; Teshima S; Yasuda T; Ito S; Yoshikawa T; Sano T; Sasako M
    Eur J Surg Oncol; 2023 Apr; 49(4):838-844. PubMed ID: 36424261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
    Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer.
    Nishibeppu K; Komatsu S; Ichikawa D; Imamura T; Kosuga T; Okamoto K; Konishi H; Shiozaki A; Fujiwara H; Otsuji E
    BMC Cancer; 2018 Jan; 18(1):108. PubMed ID: 29382310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy.
    Bilici A; Selcukbiricik F
    Tumour Biol; 2015 Aug; 36(8):6191-9. PubMed ID: 25761877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer.
    Sawaki K; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
    Cancer Med; 2020 Aug; 9(15):5392-5399. PubMed ID: 32515147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 9. Differences in risk factors between patterns of recurrence in patients after curative resection for advanced gastric carcinoma.
    Nakanishi Y; Ohara M; Domen H; Shichinohe T; Hirano S; Ishizaka M
    World J Surg Oncol; 2013 May; 11():98. PubMed ID: 23683476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraoperative blood loss is a critical risk factor for peritoneal recurrence after curative resection of advanced gastric cancer.
    Kamei T; Kitayama J; Yamashita H; Nagawa H
    World J Surg; 2009 Jun; 33(6):1240-6. PubMed ID: 19308640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection.
    Li F; Zhang R; Liang H; Liu H; Quan J
    J Surg Oncol; 2013 Feb; 107(2):130-5. PubMed ID: 22949400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multi-institutional dataset.
    Nakagawa N; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
    Cancer Med; 2018 Dec; 7(12):6020-6029. PubMed ID: 30411544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The patterns and timing of recurrence after curative resection for gastric cancer in China.
    Liu D; Lu M; Li J; Yang Z; Feng Q; Zhou M; Zhang Z; Shen L
    World J Surg Oncol; 2016 Dec; 14(1):305. PubMed ID: 27931221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
    Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
    Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence in early gastric cancer--presence of micrometastasis in lymph node of node negative early gastric cancer patient with recurrence.
    Saito H; Osaki T; Murakami D; Sakamoto T; Kanaji S; Ohro S; Tatebe S; Tsujitani S; Ikeguchi M
    Hepatogastroenterology; 2007 Mar; 54(74):620-4. PubMed ID: 17523336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and recurrence pattern in node-negative advanced gastric cancer.
    Lee IS; Yook JH; Kim TH; Kim HS; Kim KC; Oh ST; Kim BS
    Eur J Surg Oncol; 2013 Feb; 39(2):136-40. PubMed ID: 23148932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
    Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
    Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor size  ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.
    Tsutsuyama M; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
    World J Surg; 2020 Jan; 44(1):194-201. PubMed ID: 31552460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for recurrence in stage II and III gastric cancer patients receiving a curative resection and postoperative adjuvant chemotherapy.
    Tsujinaka T; Shiozaki H; Yano M; Kikkawa N; Takami M; Monden M
    Oncol Rep; 2001; 8(1):33-8. PubMed ID: 11115565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.